{"id":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain medications","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Thrombolytics","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Selective serotonin reuptake inhibitors (SSRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Serotonin-norepinephrine reuptake inhibitors (SNRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of immunosuppression"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Interferons","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Thalidomide","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Lenalidomide","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Pazopanib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sunitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Vemurafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Dabrafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Trametinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ipilimumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Nivolumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Pembrolizumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Atezolizumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Durvalumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Avelumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ceritinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Crizotinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Lapatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Neratinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Palbociclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ribociclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Abemaciclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Everolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Temsirolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Fedratinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ponatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Dasatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Nilotinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Bosutinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Imatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sorafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sunitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Regorafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Cabozantinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Lenvatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Axitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Tivozanib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Pazopanib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Vemurafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Dabrafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Trametinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ipilimumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Nivolumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Pembrolizumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Atezolizumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Durvalumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Avelumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ceritinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Crizotinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Lapatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Neratinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Palbociclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ribociclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Abemaciclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Everolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Temsirolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Fedratinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ponatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Dasatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Nilotinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Bosutinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Imatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sorafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sunitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Regorafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Cabozantinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Lenvatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Axitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Tivozanib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Pazopanib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Vemurafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Dabrafenib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Trametinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ipilimumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Nivolumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Pembrolizumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Atezolizumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Durvalumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Avelumab","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ceritinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Crizotinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Lapatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Neratinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Palbociclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ribociclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Abemaciclib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Everolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Sirolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Temsirolimus","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Tofacitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Upadacitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Baricitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ruxolitinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Fedratinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Ponatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Dasatinib","action":"Avoid","effect":"Decreased efficacy of vaccine"},{"drug":"Nilotinib","action":"Avoid","effect":"Decreased efficacy of vaccine"}],"commonSideEffects":[{"effect":"Headache","drugRate":"6.2%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":48,"totalAffected":3,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":48,"totalAffected":0,"trialsReporting":1}],"contraindications":["The BNT162b2 vaccine is not recommended for individuals with a known history of severe allergic reactions to any vaccine's components.","The use of this vaccine in children under the age of 5 is not yet recommended.","Pregnant or breastfeeding women must consult a doctor or pharmacist before receiving this vaccine."],"specialPopulations":{"Pregnancy":"All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the risk of birth defects and loss has been estimated at 2% to 4% and 15% to 20%, respectively. Animal data showed no adverse developmental findings.","Geriatric use":"In Study 4, of 5,081 recipients who received COMIRNATY as the first booster dose, 23.1% (n = 1,175) were 65 years of age and older and 5.2% (n = 265) were 75 years of age and older. In Study 5, of 726 recipients who received Pfizer-BioNTech COVID-19 Vaccine, Bivalent as the second booster dose, 21.9% (n = 159) were 65 years of age and older and 4.8% (n = 35) were 75 years of age and older.","Paediatric use":"Clinical studies included participants 5 years through 11 years of age previously vaccinated with a 2-dose primary series. In Study 4, of 5,081 recipients who received COMIRNATY as the first booster dose, pediatric participants were included.","Renal impairment":"","Hepatic impairment":""},"seriousAdverseEvents":[{"event":"Atrial flutter","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Coronary artery disease","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Prostate cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Ischaemic stroke","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Spinal cord herniation","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hydronephrosis","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Renal cyst","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:12:38.949654+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:12:49.883802+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:12:32.632821+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:12:51.390203+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:12:31.070524+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:12:51.390196+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:12:51.390183+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:33:36.900369+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T07:55:50.483250+00:00"}},"allNames":"bnt162b2 bivalent (original/omicron ba.4/ba.5) 30 mcg","offLabel":[],"timeline":[],"aiSummary":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, developed by Pfizer, holds a significant market position as one of the leading COVID-19 vaccines, with three approved indications and substantial revenue potential. Its competitive advantage lies in its ability to stimulate a robust immune response, though it faces strong competition from Moderna’s mRNA-1273.222, which demonstrates greater effectiveness in preventing hospitalizations and outpatient visits, especially in older adults. A key risk is the rapid evolution of the SARS-CoV-2 virus, which may reduce the vaccine's efficacy over time, necessitating frequent updates. The pipeline outlook remains promising, with ongoing development of updated formulations like the XBB1.5 containing mRNA vaccines, which aim to maintain consistent dosing and enhance protection against emerging variants.","brandName":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Spike protein","novelty":"Best-in-class","modality":"mRNA","drugClass":"mRNA vaccine","explanation":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg is a type of mRNA vaccine that uses a piece of genetic material called messenger RNA to instruct cells in the body to produce a specific protein. This protein, known as the spike protein, is found on the surface of the SARS-CoV-2 virus. When the vaccine is administered, the mRNA is taken up by cells in the body, which then produce the spike protein. The immune system recognizes the spike protein as foreign and mounts an immune response, producing antibodies that can recognize and bind to the protein. This immune response provides protection against future infections with the SARS-CoV-2 virus.","oneSentence":"Stimulates the body's immune system to produce antibodies against the SARS-CoV-2 virus.","technicalDetail":"The vaccine uses a lipid nanoparticle (LNP) delivery system to transport the mRNA into cells, where it is translated into the spike protein. The spike protein is then recognized by the immune system, which mounts an immune response and produces antibodies against the protein. The vaccine has been shown to be highly effective in preventing severe illness and hospitalization due to COVID-19."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL5791340","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":null,"withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:33:44.507584+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"mRNA-1273.222","company":"Moderna","advantage":"greater effectiveness in preventing COVID-19-related hospitalizations and outpatient visits, with increased benefits in older adults"},{"name":"BNT162b2 monovalent","company":"Pfizer-BioNTech","advantage":"higher effectiveness for mRNA-1273.222 versus BNT162b2 Bivalent against infection"},{"name":"Updated XBB1.5 containing mRNA vaccines","company":"Moderna and Pfizer-BioNTech","advantage":"consistent in terms of dosage (50 µg for Moderna and 30 µg for Pfizer-BioNTech)"}],"genericName":"bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months through 4 years of age","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"","acronym":null,"sponsor":"BioNTech SE","isPivotal":false,"primaryCI":"","primaryHR":"","enrollment":383,"indication":"SARS-CoV-2 Infection, COVID-19","endpointCount":33,"primaryPValue":"","completionDate":"","primaryEndpoint":"Number of Participants With Solicited Local Reactions- Post Dose 1"}],"_emaApprovals":[{"date":"","name":"BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[{"nctId":"NCT05541861","groups":[{"id":"FG000","title":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","description":"Participants aged 18-55 years received an intramuscular injection of BNT162b2 Bivalent 30 micrograms (mcg) along with BNT162b4 5 mcg at Day 1."},{"id":"FG001","title":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","description":"Participants aged 18-55 years received an intramuscular injection of BNT162b2 Bivalent 30 mcg along with BNT162b4 10 mcg at Day 1. Participants who consented to receive a second dose of the study drug"},{"id":"FG002","title":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","description":"Participants aged 18-55 years received a dose of BNT162b2 Bivalent 30 mcg (Omicron BA.4/BA.5) along with BNT162b4 15 mcg at Day 1, Participants who consented to receive a second dose of the study drug"},{"id":"FG003","title":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","description":"Participants aged greater than (\\>) 55 years received a dose of BNT162b2 Bivalent 30 mcg (Omicron BA.4/BA.5) along with BNT162b4 15 mcg at Day 1. Participants who consented to receive a second dose of"},{"id":"FG004","title":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","description":"Participants aged 18-55 years received a dose of BNT162b2 Bivalent 30 mcg (Omicron BA.4/BA.5) along with BNT162b4 30 mcg at Day 1. Participants who consented to receive a second dose of the study drug"},{"id":"FG005","title":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","description":"Participants aged \\> 55 years received a dose of BNT162b2 Bivalent 30 mcg (Omicron BA.4/BA.5) along with BNT162b4 30 mcg at Day 1. Participants who consented to receive a second dose of the study drug"},{"id":"FG006","title":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","description":"Participants aged 18-55 years received two intramuscular injections of BNT162b4 30 mcg at Day 1 and 2 months post-Dose 1, respectively."},{"id":"FG007","title":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","description":"Participants aged 18-55 years received one intramuscular injection of BNT162b2 30 mcg at Day 1."},{"id":"FG008","title":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","description":"Participants aged \\>55 years received one intramuscular injection of BNT162b2 30 mcg at Day 1."}],"acronym":null,"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","counts":{"FG000":"46","FG001":"45","FG002":"45","FG003":"45","FG004":"46","FG005":"45","FG006":"22","FG007":"59","FG008":"30"}},{"type":"Safety Set- Post Dose 1","counts":{"FG000":"48","FG001":"44","FG002":"44","FG003":"43","FG004":"46","FG005":"45","FG006":"21","FG007":"59","FG008":"29"}},{"type":"Safety Set- Post Dose 2","counts":{"FG000":"0","FG001":"30","FG002":"30","FG003":"31","FG004":"37","FG005":"34","FG006":"19","FG007":"0","FG008":"0"}},{"type":"Dose 1 (At Day 1)","counts":{"FG000":"46","FG001":"44","FG002":"44","FG003":"45","FG004":"46","FG005":"45","FG006":"21","FG007":"59","FG008":"29"}},{"type":"Dose 2 (At 6 Months for Cohorts 1, 2, 3a, 3b,4a, 4b and Comparator Cohorts;at 2 Months for Cohort 5)","counts":{"FG000":"0","FG001":"30","FG002":"30","FG003":"31","FG004":"37","FG005":"34","FG006":"19","FG007":"0","FG008":"0"}},{"type":"COMPLETED","counts":{"FG000":"46","FG001":"44","FG002":"44","FG003":"45","FG004":"46","FG005":"45","FG006":"19","FG007":"59","FG008":"29"}},{"type":"NOT COMPLETED","counts":{"FG000":"0","FG001":"1","FG002":"1","FG003":"0","FG004":"0","FG005":"0","FG006":"3","FG007":"0","FG008":"1"}}],"dropWithdraws":[{"type":"Withdrawal by Subject","counts":{"FG000":"0","FG001":"0","FG002":"0","FG003":"0","FG004":"0","FG005":"0","FG006":"2","FG007":"0","FG008":"0"}},{"type":"Randomized but not dosed","counts":{"FG000":"0","FG001":"1","FG002":"1","FG003":"0","FG004":"0","FG005":"0","FG006":"1","FG007":"0","FG008":"1"}}]}],"recruitment":"","preAssignment":""}],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","acronym":null,"sponsor":"BioNTech SE","isPivotal":false,"conditions":["SARS-CoV-2 Infection","COVID-19"],"enrollment":383,"otherEndpoints":[],"primaryEndpoints":[{"type":"PRIMARY","title":"Number of Participants With Solicited Local Reactions- Post Dose 1","results":[{"value":"5","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"5","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"5","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"4","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"3","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 7 days post-dose1","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) and pre-listed (that is, solicited) in the e-diary. Solicited local reactions included: pain, erythema/redness, and induration/swelling.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Reactions- Post Dose 2","results":[{"value":"2","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"3","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 7 days post-dose 2","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) and pre-listed (that is, solicited) in the e-diary. Solicited local reactions included: pain, erythema/redness, and induration/swelling. Data for this outcome measure was not collected and analyzed for Cohort 1, and Comparator Cohorts A and B, as these Cohorts did not receive Dose 2 of the study drugs.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Events- Post Dose 1","results":[{"value":"3","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"4","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"5","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"3","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 7 days post-dose 1","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the e-diary. Solicited systemic reactions included: vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, and fever.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Events- Post Dose 2","results":[{"value":"1","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 7 days post-dose 2","description":"A solicited reaction was defined as an adverse reaction observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the e-diary. Solicited systemic reactions included: vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, and fever.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs)-Post Dose 1","results":[{"value":"11","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"4","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"8","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"6","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"8","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"5","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"13","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"5","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 28 days post-dose 1","description":"An AE was defined as any untoward medical occurrence in a participant administered with a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs)-Post Dose 2","results":[{"value":"3","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"9","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"3","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"5","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"2","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 28 days post-dose 2","description":"An AE was defined as any untoward medical occurrence in a participant administered with a pharmaceutical product, and which did not necessarily have a causal relationship with this treatment.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)-Post Dose 1","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 6 to 7 months post-dose 1 for Cohorts 1 to 4 and Comparator Cohorts; and up to 2 months post-dose 1 for Cohort 5","description":"An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death and was life-threatening. It also included any event requiring hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, caused a congenital anomaly or birth defect, or any other event determined as SAE as per medical or scientific judgment.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)-Post Dose 2","results":[{"value":"1","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"Up to 6 to 7 months post-dose 2 for Cohorts 2 to 4; and up to 3 months post-dose 2 for Cohort 5","description":"An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death and was life-threatening. It also included any event requiring hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, caused a congenital anomaly or birth defect, or any other event determined as SAE as per medical or scientific judgment.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters-Post Dose 1","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 3 post-Dose 1; at Day 7 post-dose 1","description":"Participants with hematological abnormalities for basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets were analyzed and only clinically significant abnormal data was reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters-Post Dose 2","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 7 post-dose 2","description":"Participants with hematological abnormalities for basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, monocytes, neutrophils and platelets were analyzed and only clinically significant abnormal data was reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Clinical Chemistry-Post Dose 1","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 3 post-Dose 1; at Day 7 post-dose 1","description":"Participants with laboratory abnormalities (clinical chemistry) for alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, C-reactive protein, creatinine, direct bilirubin, gamma glutamyl transferase, glucose, high sensitivity C reactive protein, indirect bilirubin, lipase, total bilirubin, troponin I type 3 and urea nitrogen were analyzed and only abnormal clinically significant data was reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant Laboratory Abnormalities: Clinical Chemistry-Post Dose 2","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 7 post-dose 2","description":"Participants with laboratory abnormalities (clinical chemistry) for alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, C-reactive protein, creatinine, direct bilirubin, gamma glutamyl transferase, glucose, high sensitivity C reactive protein, indirect bilirubin, lipase, total bilirubin, troponin I type 3 and urea nitrogen were analyzed and only clinically significant abnormal data was reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant New Electrocardiogram (ECG) Abnormalities -Post Dose 1","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 3 post-Dose 1; at Day 7 post-dose 1","description":"Participants with only clinically significant new ECG abnormalities were reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Clinically Significant New ECG Abnormalities -Post Dose 2","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 7 post-dose 2","description":"Participants with only clinically significant new ECG abnormalities were reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade 0 to Worst Grade >=3: Post-dose 1","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 3 post-dose 1; at Day 7 post-dose 1","description":"The intensity of AEs and laboratory parameters was graded by the investigator. Grades were defined as: Grade 1 - Mild; does not interfere with the trial participant's usual function; Grade 2 - Moderate; interferes to some extent with the trial participant's usual function; Grade 3 - Severe; interferes significantly with the trial participant's usual function and Grade 4 - Potentially life-threatening; life-threatening consequences, urgent intervention required. Participants with shift change from Baseline Grade 0 to Worst Grade \\>=3 were reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Shift of Laboratory Parameters (Hematology) From Baseline Grade 0 to Worst Grade >=3: Post Dose 2","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 7 post-dose 2","description":"The intensity of AEs and laboratory parameters was graded by the investigator. Grades were defined as: Grade 1 - Mild; does not interfere with the trial participant's usual function; Grade 2 - Moderate; interferes to some extent with the trial participant's usual function; Grade 3 - Severe; interferes significantly with the trial participant's usual function and Grade 4 - Potentially life-threatening; life-threatening consequences, urgent intervention required. Participants with shift change from Baseline Grade 0 to Worst Grade \\>=3 were reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Shift of Laboratory Parameters (Clinical Chemistry) From Baseline Grade 0 to Worst Grade >=3: Post Dose 1","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG007","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG006","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG008","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 3 post-dose 1; at Day 7 post-dose 1","description":"The intensity of AEs and laboratory parameters was graded by the investigator. Grades were defined as: Grade 1 - Mild; does not interfere with the trial participant's usual function; Grade 2 - Moderate; interferes to some extent with the trial participant's usual function; Grade 3 - Severe; interferes significantly with the trial participant's usual function and Grade 4 - Potentially life-threatening; life-threatening consequences, urgent intervention required. Participants with shift change from Baseline Grade 0 to Worst Grade \\>=3 were reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"},{"type":"PRIMARY","title":"Number of Participants With Shift of Laboratory Parameters (Clinical Chemistry) From Baseline Grade 0 to Worst Grade >=3: Post-dose 2","results":[{"value":"0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"1","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"","upperLimit":""},{"value":"0","spread":"","groupId":"OG005","groupTitle":"Cohort 5: BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"","upperLimit":""}],"analyses":[],"paramType":"COUNT_OF_PARTICIPANTS","timeFrame":"At Day 7 post-dose 2","description":"The intensity of AEs and laboratory parameters was graded by the investigator. Grades were defined as: Grade 1 - Mild; does not interfere with the trial participant's usual function; Grade 2 - Moderate; interferes to some extent with the trial participant's usual function; Grade 3 - Severe; interferes significantly with the trial participant's usual function and Grade 4 - Potentially life-threatening; life-threatening consequences, urgent intervention required. Participants with shift change from Baseline Grade 0 to Worst Grade \\>=3 were reported in the outcome measure.","unitOfMeasure":"Participants","reportingStatus":"POSTED"}],"secondaryEndpoints":[{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) for SARS-CoV-2 Neutralizing Antibody Ancestral Strain-Post Dose 1","results":[{"value":"12666.7","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"9744.2","upperLimit":"16465.6"},{"value":"13017.3","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"9639.5","upperLimit":"17578.7"},{"value":"9571.7","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"7120.1","upperLimit":"12867.4"},{"value":"14553.1","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"11441.6","upperLimit":"18510.9"},{"value":"10326.7","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"7827.3","upperLimit":"13624.4"},{"value":"10126.2","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"7730.8","upperLimit":"13263.9"},{"value":"12767.2","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"9848.9","upperLimit":"16550.1"},{"value":"14628.7","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"10394.8","upperLimit":"20587.0"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"At Pre-dose and Day 28 post dose-1","description":"GMTs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody ancestral strain were measured by valid assay method. Data for this outcome measure was not planned to be collected and analyzed for Cohort 5.","unitOfMeasure":"titers","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) for SARS-CoV-2 Neutralizing Antibody Ancestral Strain-Post Dose 2","results":[{"value":"5940.9","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"4413.3","upperLimit":"7997.2"},{"value":"10032.4","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"6551.6","upperLimit":"15362.6"},{"value":"7329.5","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"4942.9","upperLimit":"10868.6"},{"value":"12884.0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"9244.3","upperLimit":"17956.7"},{"value":"7782.0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"4992.9","upperLimit":"12129.2"},{"value":"6294.6","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"3683.9","upperLimit":"10755.4"},{"value":"5238.7","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"3869.6","upperLimit":"7092.2"},{"value":"5490.6","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"3394.2","upperLimit":"8881.9"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"At Pre-dose 2 and Day 28 post-dose 2","description":"GMTs for SARS-CoV-2 neutralizing antibody ancestral strain were measured by valid assay method. Data for this outcome measure was not planned to be collected and analyzed for Cohort 5.","unitOfMeasure":"titers","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) for SARS-CoV-2 Neutralizing Antibody Omicron Strains (SARS-CoV-2 Omicron BA.4/BA.5)- Post Dose 1","results":[{"value":"5540.9","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"3878.4","upperLimit":"7916.1"},{"value":"6801.2","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"5000.7","upperLimit":"9249.9"},{"value":"4690.6","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"3313.1","upperLimit":"6640.9"},{"value":"6303.1","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"4775.2","upperLimit":"8319.8"},{"value":"5913.9","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"4330.8","upperLimit":"8075.8"},{"value":"3907.0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"2802.3","upperLimit":"5447.3"},{"value":"6323.4","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"4390.6","upperLimit":"9107.0"},{"value":"6552.0","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"3927.7","upperLimit":"10929.8"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"At Pre-dose and Day 28 post-dose 1","description":"GMTs for SARS-CoV-2 Omicron BA.4/BA.5 strain were measured by valid assay method.","unitOfMeasure":"titers","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) for SARS-CoV-2 Neutralizing Antibody Omicron Strains (SARS-CoV-2 Omicron BA.4/BA.5)- Post Dose 2","results":[{"value":"2597.0","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"1733.5","upperLimit":"3890.5"},{"value":"6506.3","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"4270.1","upperLimit":"9913.7"},{"value":"1750.6","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"1223.9","upperLimit":"2504.1"},{"value":"2089.7","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"1422.2","upperLimit":"3070.4"},{"value":"2179.6","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"1583.2","upperLimit":"3000.7"},{"value":"1663.4","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"1057.0","upperLimit":"2617.8"},{"value":"2649.8","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"1906.0","upperLimit":"3683.8"},{"value":"2610.0","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"1427.1","upperLimit":"4773.3"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"At Pre-dose 2 and Day 28 post-dose 2","description":"GMTs for SARS-CoV-2 Omicron BA.4/BA.5 strain were measured by valid assay method. Data for this outcome measure was not planned to be collected and analyzed for Cohort 5.","unitOfMeasure":"titers","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) for SARS-CoV-2 Neutralizing Antibody Omicron Strains (SARS-CoV-2 Omicron XBB1.5)- Post Dose 2","results":[{"value":"2493.1","spread":"","groupId":"OG000","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"1572.4","upperLimit":"3953.0"},{"value":"3325.2","spread":"","groupId":"OG001","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"2110.1","upperLimit":"5239.8"},{"value":"3042.7","spread":"","groupId":"OG002","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"1850.6","upperLimit":"5002.5"},{"value":"1935.9","spread":"","groupId":"OG003","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"1061.7","upperLimit":"3530.1"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"At Pre-dose 2 and Day 28 post-dose 2","description":"GMTs for SARS-CoV-2 Omicron XBB1.5 strain were measured by valid assay method.","unitOfMeasure":"titers","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 Ancestral Strain-Post Dose 1","results":[{"value":"3.4","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"2.7","upperLimit":"4.4"},{"value":"2.9","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"2.1","upperLimit":"4.0"},{"value":"3.3","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"2.4","upperLimit":"4.6"},{"value":"2.3","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"1.8","upperLimit":"3.1"},{"value":"3.4","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"2.6","upperLimit":"4.5"},{"value":"4.2","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"3.2","upperLimit":"5.5"},{"value":"3.7","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"2.8","upperLimit":"4.9"},{"value":"3.6","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"2.3","upperLimit":"5.7"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"From pre-dose 1 to 28 days post-dose 1","description":"GMFRs are defined as ratios of the results after vaccination (that is 28 days post-dose 1) to the results before vaccination (that is pre-dose 1).","unitOfMeasure":"ratio","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 Ancestral Strain-Post Dose 2","results":[{"value":"2.2","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"1.4","upperLimit":"3.6"},{"value":"2.0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"1.2","upperLimit":"3.5"},{"value":"2.1","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"1.4","upperLimit":"3.0"},{"value":"2.6","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"1.8","upperLimit":"3.6"},{"value":"2.8","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"1.7","upperLimit":"4.7"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"From pre-dose 2 to 28 days post-dose 2","description":"GMFRs are defined as ratios of the results after vaccination (that is 28 days post-dose 2) to the results before vaccination (that is pre-dose 2). Data for this outcome measure was not planned to be collected and analyzed for Cohorts 1, 5 and Comparator Cohorts A and B.","unitOfMeasure":"ratio","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 Omicron Strain (OMI BA.4/BA.5)-Post Dose 1","results":[{"value":"5.4","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"3.6","upperLimit":"8.1"},{"value":"4.5","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"3.0","upperLimit":"6.8"},{"value":"4.4","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"3.0","upperLimit":"6.5"},{"value":"3.1","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"2.2","upperLimit":"4.4"},{"value":"5.8","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"4.3","upperLimit":"7.8"},{"value":"5.9","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"4.2","upperLimit":"8.2"},{"value":"4.3","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"3.2","upperLimit":"5.7"},{"value":"5.4","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"3.4","upperLimit":"8.7"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"From pre-dose 1 to 28 days post-dose 1","description":"GMFRs are defined as ratios of the results after vaccination (that is 28 days post-dose 1) to the results before vaccination (that is pre-dose 1).","unitOfMeasure":"ratio","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 Omicron Strain (OMI BA.4/BA.5)-Post Dose 2","results":[{"value":"4.4","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"2.4","upperLimit":"8.0"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"From pre-dose 2 to 28 days post-dose 2","description":"GMFRs are defined as ratios of the results after vaccination (that is 28 days post-dose 2) to the results before vaccination (that is pre-dose 2).","unitOfMeasure":"ratio","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 Omicron Strain (Omicron XBB1.5)-Post Dose 2","results":[{"value":"5.6","spread":"","groupId":"OG000","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"3.7","upperLimit":"8.5"},{"value":"7.8","spread":"","groupId":"OG001","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"5.5","upperLimit":"11.1"},{"value":"4.9","spread":"","groupId":"OG002","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"3.2","upperLimit":"7.4"},{"value":"6.5","spread":"","groupId":"OG003","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"4.2","upperLimit":"10.2"}],"analyses":[],"paramType":"GEOMETRIC_MEAN","timeFrame":"From Pre-dose 2 to Day 28 post-dose 2","description":"GMFRs are defined as ratios of the results after vaccination (that is 28 days post-dose 2) to the results before vaccination (that is pre-dose 2).","unitOfMeasure":"ratio","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse to SARS-CoV-2 Ancestral Strain-Post Dose 1","results":[{"value":"32.5","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"18.6","upperLimit":"49.1"},{"value":"30.8","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"17.0","upperLimit":"47.6"},{"value":"35.7","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"21.6","upperLimit":"52.0"},{"value":"20.0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"9.1","upperLimit":"35.6"},{"value":"38.5","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"23.4","upperLimit":"55.4"},{"value":"43.9","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"28.5","upperLimit":"60.3"},{"value":"50.0","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"36.3","upperLimit":"63.7"},{"value":"41.4","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"23.5","upperLimit":"61.1"}],"analyses":[],"paramType":"NUMBER","timeFrame":"At Day 28 post-dose 1","description":"Seroresponse was defined as achieving \\>=4-fold rise from baseline (that is, pre-dose).","unitOfMeasure":"percentage of participants","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse to SARS-CoV-2 Ancestral Strain-Post Dose 2","results":[{"value":"24.0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"9.4","upperLimit":"45.1"},{"value":"16.0","spread":"","groupId":"OG001","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"4.5","upperLimit":"36.1"},{"value":"32.1","spread":"","groupId":"OG002","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"15.9","upperLimit":"52.4"},{"value":"23.1","spread":"","groupId":"OG003","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"9.0","upperLimit":"43.6"},{"value":"27.3","spread":"","groupId":"OG004","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"10.7","upperLimit":"50.2"}],"analyses":[],"paramType":"NUMBER","timeFrame":"At Day 28 post-dose 2","description":"Seroresponse was defined as achieving \\>=4-fold rise from baseline (that is, pre-dose).","unitOfMeasure":"percentage of participants","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron Strains (OMI BA.4/BA.5)- Post Dose 1","results":[{"value":"52.5","spread":"","groupId":"OG000","groupTitle":"Cohort 1: BNT162b2 Bivalent 30 mcg + BNT162b4 5 mcg (Aged 18-55 Years)","lowerLimit":"36.1","upperLimit":"68.5"},{"value":"46.2","spread":"","groupId":"OG001","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"30.1","upperLimit":"62.8"},{"value":"47.6","spread":"","groupId":"OG002","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"32.0","upperLimit":"63.6"},{"value":"30.0","spread":"","groupId":"OG003","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"16.6","upperLimit":"46.5"},{"value":"59.0","spread":"","groupId":"OG004","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"42.1","upperLimit":"74.4"},{"value":"61.0","spread":"","groupId":"OG005","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"44.5","upperLimit":"75.8"},{"value":"44.6","spread":"","groupId":"OG006","groupTitle":"Comparator A: BNT162b2 Bivalent 30 mcg (Aged 18-55 Years)","lowerLimit":"31.3","upperLimit":"58.5"},{"value":"55.2","spread":"","groupId":"OG007","groupTitle":"Comparator B: BNT162b2 Bivalent 30 mcg (Aged >55 Years)","lowerLimit":"35.7","upperLimit":"73.6"}],"analyses":[],"paramType":"NUMBER","timeFrame":"At Day 28 post-dose 1","description":"Seroresponse was defined as achieving \\>=4-fold rise from baseline (that is, pre-dose).","unitOfMeasure":"percentage of participants","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron Strains (OMI BA.4/BA.5)- Post Dose 2","results":[{"value":"44.0","spread":"","groupId":"OG000","groupTitle":"Cohort 2: BNT162b2 Bivalent 30 mcg + BNT162b4 10 mcg (Aged 18-55 Years)","lowerLimit":"24.4","upperLimit":"65.1"}],"analyses":[],"paramType":"NUMBER","timeFrame":"At Day 28 post-dose 2","description":"Seroresponse was defined as achieving \\>=4-fold rise from baseline (that is, pre-dose).","unitOfMeasure":"percentage of participants","reportingStatus":"POSTED"},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron Strains (SARS-CoV-2 Omicron XBB1.5)- Post Dose 2","results":[{"value":"64.0","spread":"","groupId":"OG000","groupTitle":"Cohort 3a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged 18-55 Years)","lowerLimit":"42.5","upperLimit":"82.0"},{"value":"77.8","spread":"","groupId":"OG001","groupTitle":"Cohort 3b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 15 mcg (Aged >55 Years)","lowerLimit":"57.7","upperLimit":"91.4"},{"value":"50.0","spread":"","groupId":"OG002","groupTitle":"Cohort 4a: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged 18-55 Years)","lowerLimit":"29.9","upperLimit":"70.1"},{"value":"72.7","spread":"","groupId":"OG003","groupTitle":"Cohort 4b: BNT162b2 Bivalent/Monovalent 30 mcg + BNT162b4 30 mcg (Aged >55 Years)","lowerLimit":"49.8","upperLimit":"89.3"}],"analyses":[],"paramType":"NUMBER","timeFrame":"At Day 28 post-dose 2","description":"Seroresponse was defined as achieving \\>=4-fold rise from baseline (that is, pre-dose).","unitOfMeasure":"percentage of participants","reportingStatus":"POSTED"}]}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA therapeutics","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T08:33:44.507584+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}